[1]
“Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study”, J of Skin, vol. 7, no. 2, p. s180, Mar. 2023, doi: 10.25251/skin.7.supp.180.